When screening for depression in adolescents with type 1 diabetes, the Patient Health Questionnaire (PHQ)-9 had a higher sensitivity when compared with the PROMIS (Patient-Reported Outcomes Measurement Information System), according to research results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019.

In a comparison study, researchers administered 2 depression screening questionnaires, the PROMIS and PHQ-9, on the same day (n = 20), within 3 months (n = 17), or within 6 months (n = 11) to a cohort of adolescents aged 11 to 17 years who had type 1 diabetes. All adolescents completed the PHQ-9. For PROMIS, both the patient and a parent completed the questionnaire (PROMIS-Ch and PROMIS-P, respectively).

Related Articles

Researchers reported that individuals with no or mild risk for depression on the PHQ-9 had a PROMIS-Ch or PROMIS-P score >1.5 standard deviation (SD). Clinical evaluation confirmed the risk for depression in 5 of 6 individuals who scored at moderate/severe risk on the PHQ-9, but only 2 of the 5 individuals based on the PROMIS-Ch (>1.5 SD) and 1 of 5 based on the PROMIS-P (>2 SD).

Of 4 participants with documented suicidal ideation, the mean PHQ-9 score was 18.4±6.7, indicating a moderate/severe risk; however, the PROMIS risk scores were not consistently high in these patients (PROMIS-Ch >1.5 SD in 2 of 4 adolescents; PROMIS-P >1.5 SD in 1 of 4 adolescents).

“Both surveys distinguished children at moderate/severe risk of depression from those with no/mild risk. Neither PROMIS survey distinguished between children who were at mild or no risk on PHQ-9…. When screening for depression in adolescents, PHQ-9 had a higher sensitivity when compared to PROMIS,” the researchers concluded.

Reference

Nadella S, Fritz SA, Muir AB. Variables in depression screening using PHQ-9 and PROMIS in adolescents with T1DM. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco, CA. Poster 1373-P.

This article originally appeared on Endocrinology Advisor